FDA 483 - Nanophase Technologies Corporation - January 09, 2026

An FDA inspection of Solesence, Inc., an API manufacturer in Romeoville, IL, revealed a significant issue where processes for API production were not followed in writing. Specifically, an operator began a coating batch without an issued batch record, and reactor cells were found operating outside specified flow ranges. These conditions indicate a lack of adherence to established manufacturing procedures.